A real-world study at MSK reveals promising efficacy and safety of second-generation BTK inhibitors in mantle cell lymphoma treatment, influencing future guidelines.
Lynnette Henshaw, PharmD, BCOP
Advertisement
Articles by Lynnette Henshaw, PharmD, BCOP
Advertisement
Latest Updated Articles
Expert: Assessing the Role of Second-Generation BTK Inhibitors in Frontline Mantle Cell Lymphoma TreatmentPublished: October 1st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Bacteria and Fungi in the Mouth Found to Drive Pancreatic Cancer Risk
2
How the FDA Is Using AI to Monitor Drug Advertising and Ensure Compliance
3
FDA Approves Lurbinectedin Combination Regimen in Extensive-Stage SCLC
4
Building an Opioid Stewardship Program in Cancer Care: Pharmacist Roles, Challenges, and Patient Safety
5
